Biocon (BIOCON.EQ-IN)

Add a New Bulls Reason Company: Biocon (BIOCON.EQ-IN) Current price: Headline: (100 character max) Analysis: Cancel 0% agree 0 votes   Desire to bring out India's first blockbuster drug. Top Contributor: Vishwanath Donti | Created when NSE:BIOCON.EQ was $141.65 | Edit | History The entire team at biocon is geared up towards delivering a blockbuster drug from India, which would truely be a milestone in the history of the Indian Pharmaceutical Industry. (100 character max) Cancel 0% agree 0 votes   Excellent management Top Contributor: Vishwanath Donti | Created when NSE:BIOCON.EQ was $141.65 | Edit | History Management is truly exceptional and well aligned with shareholder interests beginning with Ms. Kiran Mazumdar Shaw. (100 character max) Cancel 0% agree 0 votes   Biopharmaceuticals Top Contributor: Vishwanath Donti | Created when NSE:BIOCON.EQ was $141.65 | Edit | History Generic Insulin, Glargine are good generic products, requiring niche manufacturing skills, and so can command a bit more premium. US and European markets are just opening up to bio-generics. (100 character max) Cancel 0% agree 0 votes   Syngene Top Contributor: Vishwanath Donti | Created when NSE:BIOCON.EQ was $141.65 | Edit | History The outsourcing model, with the benefit of lower costs and high quality skilled scientists. Further their niche in biochemistry and related skills is a differentiator, and most of the new development of drugs is in this area. (100 character max) Cancel 0% agree 0 votes   Clinigene Top Contributor: Vishwanath Donti | Created when NSE:BIOCON.EQ was $141.65 | Edit | History Outsourced clinical trials, and setting up of an ODC, 'One-Box' model can benefit a lot of large pharma players. (100 character max) Cancel 0% agree 0 votes   Oral Insulin Top Contributor: Vishwanath Donti | Created when NSE:BIOCON.EQ was $141.65 | Edit | History IN-105 is a very impressive product, and could replace injectable insulin. Further the company manufactures insulin, so they can manage the cost of the product to be quite competitive. (100 character max) Cancel

Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.